Adding bemarituzumab to chemo may up survival in advanced FGFR2b+, HER2- gastric cancer
Adding bemarituzumab to mFOLFOX6 significantly improved survival outcomes and response rate compared with mFOLFOX6 alone in patients FGFR2b-positive, HER2-negative gastric cancer, according to the FIGHT study presented at the 2021 ASCO GI Cancer Symposium.
Adding bemarituzumab to chemo may up survival in advanced FGFR2b+, HER2- gastric cancer
11 Mar 2021